Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPINET phase 3 trial of lanreotide in metastatic or unresectable lung neuroendocrine tumors
NL-OMON49581Phase 3Completed
- Sponsor
- Ipsen
- Start
- Jan 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in bronchial neuroendocrine tumor comparing Lanreotide plus best supportive care, Placebo plus best supportive care and Open-label lanreotide treatment phase (3 arms). Primary endpoint: Primary progression-free survival. Started Jan 2018; status: completed.
02
Drugs
lanreotide
03
Conditions
bronchial neuroendocrine tumor
Beyond the preview
Go deeper on NL-OMON49581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49581.